Patent analytics for a molecule — in minutes
Pick an INN — get a ready patent clearance report: patent statuses, what can be worked around or challenged, and safe generic launch dates. Compiled by specialists, by hand.
in the storefront
done by humans
right after payment
launch dates
Until the next patent reports
We add 1 to 3 new molecules every week. The next batch is coming soon.
More than just a search
We review almost a dozen databases to gather exhaustive information on a molecule and not miss a single important patent document. Modern databases make searching easier, but it is our team of specialists that selects only what is genuinely relevant to the molecule, its use and its form.
Patent statuses
What is an absolute blocker, what can be worked around or challenged, and what poses no threat.
Day-One Launch
Dates when a generic or biosimilar can be safely launched, with explanations.
Ready .pdf
A competitive-intelligence and patent dossier: Russian sales, competitors, RF/EAPO patents, grounds for invalidation and entry opportunities — in a single PDF.
Currency
A search is current as of its date and for about six months, after which it is updated.
Featured molecules
Готовый аналитический отчёт по нусинерсену (Спинраза®) — первому в мире патогенетическому препарату для терапии спинальной мышечной атрофии 5q (антисмысловой олигонуклеотид, Biogen/Ionis). В…
Готовый аналитический отчёт по реслизумабу (Cinqair®/Cinqaero®) — гуманизированному моноклональному антителу против IL-5 (Teva) для дополнительной терапии тяжёлой эозинофильной астмы. В одном PDF:…
Готовый аналитический отчёт по инаксаплину (VX-147) — исследуемому пероральному ингибитору канала APOL1 (Vertex) для APOL1-опосредованной болезни почек. На момент подготовки препарат не…
Готовый аналитический отчёт по меглюмина акридонацетату (Циклоферон®, таблетки ППО) — низкомолекулярному индуктору интерферона (НТФФ «Полисан») для иммуномодулирующей и противовирусной терапии. В одном…
Готовый аналитический отчёт по пиротинибу (Irene®) — пероральному необратимому ингибитору тирозинкиназы HER2/EGFR (Jiangsu Hengrui, КНР) для терапии HER2-положительного рака молочной железы. В…
Готовый аналитический отчёт по элиглустату (Cerdelga®) — пероральному ингибитору глюкозилцерамид-синтазы (Sanofi Genzyme) для длительной терапии болезни Гоше 1 типа у взрослых с…
Ten sections in every report
The report has grown from a list of patents into a full dossier: the molecule’s commercial profile and actual Russian sales, the competitive landscape with manufacturing chains, a patent breakdown for RF/EAPO, worked-out grounds for invalidation, and an assessment of entry opportunities. It opens with a decision summary, followed by ten numbered sections.
Summary and methodology
What the molecule is, who the originator is, how the report was built and the status of each source. It also carries a decision summary: condensed conclusions on freedom to operate, the entry date and the justified alternatives.
Drug overview
INN and development codes, modality, mechanism of action, pharmacokinetics, dosage forms, trade names and marketing-authorisation holders, orphan and essential-drugs status, entry barriers.
Sales in the Russian Federation
Actual sales for the INN over several years and the latest half-year: revenue, packs, average price, dynamics. The therapy cluster and the originator’s replacement by generics in market-share terms.
Development history and regulatory timeline
A dated timeline: the science, patent-family priorities, regulatory approvals, Russian registrations, patent lapses and reinstatements, pricing decisions and litigation events.
Market significance
Therapeutic value and evidence base, the size and nature of the market, what is driving its growth or contraction, position within the therapeutic class, price regulation, unmet needs and threats to the model.
Competitive landscape
Marketing-authorisation holders with their manufacturing chains and API localisation, direct generics or biosimilars, in-class competitors, foreign applicants and the originator’s technological response.
Patent protection — RF/EAPO
A breakdown of every IP right: the substance of protection by independent claim and our assessment — blocking, non-blocking or conditional. The safe launch date and what may lawfully be done before it.
Challenging the patent layer and legal disputes
What Rospatent and the courts have already tested, which grounds are closed and which still work. Prior-art sources with an applicability rating, how to prioritise effort across patents, and a register of disputes.
Entry opportunities — freedom to operate
Entry strategies by protection layer with a viability rating: design-arounds by structure and by formulation, indication carve-outs, separating API from finished product, statutory mechanisms, Bolar, export.
Routes to the API and manufacturing
The synthesis route or manufacturing paradigm, building blocks, purification, critical quality points, specifications, the finished form’s composition and technology, localisation, CAPEX and the regulatory pathway.
- №2372Russian patent attorney
- №613Eurasian patent attorney
- с 2010Intellectual property in pharma
Instant search — backed by a full-service bureau
The storefront is a unique service giving instant access to a patent search by INN. At the same time PCT GURU operates as a full-service patent bureau: the team includes not only patent specialists but also lawyers, marketers and designers, and works with scientists, technologists and specialists in the registration of supplements and medicines.
Can’t find the molecule you need?
Write to us — we’ll prepare a patent clearance report for your INN and add it to the storefront.